Top Section/Ad
Top Section/Ad
Most recent
Calendar quirk could keep issuance going in December
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
◆ Single digit premiums offered ◆ Reverse Yankees dominating euro supply ◆ Floaters proving popular with multi-tranche issuers
More articles/Ad
More articles/Ad
More articles
-
Politicians across Europe are interested in the idea of the European Central Bank writing off the government bonds it holds, but this looks tricky and potentially not so useful after all. -
Political volatility might finally be biting in Peru, with Fitch putting the country's rating on negative outlook.
-
Europe’s corporate bond investors are starting to make bets that industries battered by the coronavirus pandemic and crossover-rated names are going to be the performers of 2021, even though speculative grade defaults reached a post-global financial crisis high in November.
-
The significant risk transfer market is usually at its busiest in December, as issuers hope to gain balance sheet benefits by year-end. But 2020 has seen a pullback from investors who have blamed a lack of credit data brought about by Covid-19 payment moratoria.
-
A G30 committee led by Mario Draghi and Raghuram Rajan has outlined proposals for governments looking to deal with the surging corporate distress caused by the pandemic. The paper, published on Monday, recommends better restructuring laws, equity infusions, business interruption reinsurance and targeted credit for the most vulnerable companies.
-
Cellectis, the French gene-editing company, has launched a $100m US capital raising to help fund its research and development operations. The sector has had a record year for issuance in 2020, as the Covid-19 pandemic has concentrated minds on global healthcare innovation.
